Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TBPH
stocks logo

TBPH

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
46.17M
+146.19%
1.078
-447.85%
18.13M
+17.79%
-0.117
-56.79%
19.60M
-25.18%
-0.113
-110.49%
Estimates Revision
The market is revising Downward the revenue expectations for Theravance Biopharma, Inc. (TBPH) for FY2025, with the revenue forecasts being adjusted by -5.01% over the past three months. During the same period, the stock price has changed by 34.05%.
Revenue Estimates for FY2025
Revise Downward
down Image
-5.01%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+30.07%
In Past 3 Month
Stock Price
Go Up
up Image
+34.05%
In Past 3 Month
Wall Street analysts forecast TBPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TBPH is 28.60 USD with a low forecast of 13.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast TBPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TBPH is 28.60 USD with a low forecast of 13.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 18.700
sliders
Low
13.00
Averages
28.60
High
42.00
Current: 18.700
sliders
Low
13.00
Averages
28.60
High
42.00
BTIG
Buy
upgrade
$25 -> $40
2025-11-26
Reason
BTIG
Price Target
$25 -> $40
2025-11-26
upgrade
Buy
Reason
BTIG raised the firm's price target on Theravance Biopharma to $40 from $25 and keeps a Buy rating on the shares. The firm is revisiting its annualized net price for ampreloxetine in nOH and lowering standalone operating expense assumptions to better reflect a rare disease launch, the analyst tells investors in a research note.
H.C. Wainwright
Douglas Tsao
Buy
maintain
$15 -> $20
2025-11-11
Reason
H.C. Wainwright
Douglas Tsao
Price Target
$15 -> $20
2025-11-11
maintain
Buy
Reason
H.C. Wainwright analyst Douglas Tsao raised the firm's price target on Theravance Biopharma to $20 from $15 and keeps a Buy rating on the shares following the Q3 report. Net sales of Yupelri reached an all-time high of $71.4M, the analyst tells investors in a research note. The firm upped estimates for 2026 and beyond.
B. Riley
Mayank Mamtani
initiated
$28
2025-09-12
Reason
B. Riley
Mayank Mamtani
Price Target
$28
2025-09-12
initiated
Reason
B. Riley analyst Mayank Mamtani initiated coverage of Theravance Biopharma with a Buy rating and $28 price target. The firm says Theravanc is a fully integrated biopharma company with a track record of discovering, developing and commercializing respiratory therapies. The company, after monetizing non-core asset Trelegy, is well positioned to benefit from a recent strategic review process aimed at unlocking shareholder value, the analyst tells investors in a research note.
BTIG
Buy
maintain
$24 -> $25
2025-06-27
Reason
BTIG
Price Target
$24 -> $25
2025-06-27
maintain
Buy
Reason
BTIG raised the firm's price target on Theravance Biopharma to $25 from $24 and keeps a Buy rating on the shares. Yupelri has been approved in China, triggering the $7.5M milestone payment owed to the company, the analyst tells investors in a research note. Looking ahead, Theravance is eligible to receive up to $37.5M in sales-based milestones and 14%-20% tiered royalties on Yupelri net sales in China in addition to the milestone payment, the firm added.
JonesResearch
Buy
initiated
$24
2025-06-17
Reason
JonesResearch
Price Target
$24
2025-06-17
initiated
Buy
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$15
2025-02-27
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$15
2025-02-27
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Theravance Biopharma Inc (TBPH.O) is 26.88, compared to its 5-year average forward P/E of -53.40. For a more detailed relative valuation and DCF analysis to assess Theravance Biopharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-53.40
Current PE
26.88
Overvalued PE
116.64
Undervalued PE
-223.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-87.42
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
282.63
Undervalued EV/EBITDA
-457.48

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
9.63
Current PS
0.00
Overvalued PS
14.13
Undervalued PS
5.13
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

TBPH News & Events

Events Timeline

(ET)
2025-11-10
16:15:42
Theravance Biopharma Announces Q3 Earnings Per Share of 7 Cents, Exceeding Consensus Estimate of 5 Cents
select
2025-08-25 (ET)
2025-08-25
06:01:57
Theravance Biopharma finishes enrolling participants in CYPRESS study
select
2025-08-12 (ET)
2025-08-12
16:14:50
Theravance Biopharma reaffirms FY25 R&D expenses view $32M-$38M
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-29TipRanks
Three Stocks Poised for Significant Gains, According to Top Analysts – 11/28/2025

  • Investment Opportunities: Top-rated Wall Street analysts are recommending several stocks as Buys, indicating potential for growth from current levels.

  • Research-Based Picks: These stock selections are backed by solid research, suggesting they have significant upside potential.

  • Explore Further: Investors can click on specific tickers to delve deeper into each company and assess their suitability for investment.

  • Resource Availability: For a comprehensive list of recently rated stocks, TipRanks offers a Daily Stock Ratings & Price Targets tool.

[object Object]
Preview
6.0
11-26Benzinga
Broadcom Set to Surge by 13%? Check Out 10 Leading Analyst Predictions for Wednesday

  • Analyst Rating Changes: Keybanc, Evercore ISI, Bernstein, and Deutsche Bank made notable adjustments to price targets for various companies, including Workday, Kohl's, Zscaler, and Autodesk, while maintaining their respective ratings.

  • Price Target Increases: Companies like Kohl's, Zscaler, Autodesk, and Theravance Biopharma saw their price targets raised, indicating positive outlooks from analysts despite current share prices.

  • Price Target Decreases: Nutanix experienced a significant cut in its price target by B of A Securities, although the analyst maintained a Buy rating, reflecting mixed sentiments in the market.

  • Overall Market Sentiment: Analysts from firms like Goldman Sachs and B of A Securities expressed optimism for stocks like Broadcom and Dell, raising their price targets while maintaining positive ratings.

[object Object]
Preview
6.0
11-26Benzinga
BTIG Reaffirms Buy Rating for Theravance Biopharma, Increases Price Target to $40

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.

  • Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Theravance Biopharma Inc (TBPH) stock price today?

The current price of TBPH is 18.7 USD — it has decreased -1.01 % in the last trading day.

arrow icon

What is Theravance Biopharma Inc (TBPH)'s business?

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.

arrow icon

What is the price predicton of TBPH Stock?

Wall Street analysts forecast TBPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TBPH is 28.60 USD with a low forecast of 13.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Theravance Biopharma Inc (TBPH)'s revenue for the last quarter?

Theravance Biopharma Inc revenue for the last quarter amounts to 19.99M USD, increased 18.51 % YoY.

arrow icon

What is Theravance Biopharma Inc (TBPH)'s earnings per share (EPS) for the last quarter?

Theravance Biopharma Inc. EPS for the last quarter amounts to 0.07 USD, decreased -126.92 % YoY.

arrow icon

What changes have occurred in the market's expectations for Theravance Biopharma Inc (TBPH)'s fundamentals?

The market is revising Downward the revenue expectations for Theravance Biopharma, Inc. (TBPH) for FY2025, with the revenue forecasts being adjusted by -5.01% over the past three months. During the same period, the stock price has changed by 34.05%.
arrow icon

How many employees does Theravance Biopharma Inc (TBPH). have?

Theravance Biopharma Inc (TBPH) has 97 emplpoyees as of December 05 2025.

arrow icon

What is Theravance Biopharma Inc (TBPH) market cap?

Today TBPH has the market capitalization of 947.57M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free